Additional file 2: of Clinical outcomes in idursulfase-treated
            patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey
            (HOS)

Muenzer, Joseph; Giugliani, Roberto; Scarpa, Maurizio; Tylki-SzymaĹska, Anna; Jego, Virginie; Beck, Michael

doi:10.6084/m9.figshare.5467825.v3

13023_2017_712_MOESM2_ESM.docx (20.04 kB)

Additional file 2: of Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

Version 3 2019-08-10, 04:42

Version 2 2019-06-10, 03:30

Version 1 2017-10-04, 03:47

journal contribution

posted on 2019-08-10, 04:42 authored by Joseph Muenzer, Roberto Giugliani, Maurizio Scarpa, Anna Tylki-SzymaĹska, Virginie Jego, Michael Beck

Table S2. Median urinary glycosaminoglycan (uGAG) levels and median changes from baseline in uGAG levels in patients with data available at consecutive timepoints (year 1, year 2 and year 3 of treatment with idursulfase) (DOCX 22 kb)

History

Usage metrics

Keywords

Hunter syndrome Lysosomal storage disease Idursulfase Efficacy Disease registry

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC